BridgeBio posted $180.6 million in U.S. Attruby net product revenue in Q1 2026 — a single product, approved less than 18 months ago, already funding a $500 million share buyback authorization. That is not the profile of a company managing a launch; it is the profile of a company that has already won one and is now betting on itself to win three more.
The buyback is the most strategically revealing move in this earnings release. BridgeBio is sitting on $940 million in cash and has three NDAs queued for FDA submission within the next two quarters — BBP-418 in LGMD2I/R9 already filed, encaleret in ADH1 on deck for 1H 2026, and oral infigratinib in achondroplasia targeting Q3 2026. All three carry priority review eligibility. The decision to deploy $500 million in buybacks rather than a partnership or acquisition signals that management believes the market is mispricing the pipeline — not just Attruby’s durability, but the probability-weighted value of three near-simultaneous rare disease launches. That is an aggressive internal IRR calculation, and it sets a high accountability bar for execution over the next 18 months.
The real-world evidence campaign around Attruby deserves attention beyond the commercial narrative. A 43% reduction in diuretic intensification versus tafamidis, drawn from real-world data and now on medRxiv, is not a soft differentiation claim — diuretic escalation is a hard proxy for disease progression and hospitalization risk. Combined with the 44.7% all-cause mortality reduction at Month 54 from the open-label extension, BridgeBio is constructing a durable evidence stack that payers and formulary committees will find difficult to route around. Pfizer’s tafamidis still dominates total prescriptions, but BridgeBio is systematically closing the clinical argument. Brazil approval adds a meaningful ex-U.S. vector as that market’s ATTR-CM patient identification infrastructure matures.
The single number to track is the treatment-naïve prescribing share. BridgeBio flagged it explicitly as a growth driver, and naïve patients represent the segment where tafamidis has no incumbent advantage. If naïve-patient capture continues accelerating through Q2 and Q3, it confirms Attruby is winning on clinical merit rather than just converting dissatisfied tafamidis patients — and that distinction is what justifies both the buyback math and the confidence behind three simultaneous rare-disease launches.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
